Tech Company Financing Transactions
EPIRUS Biopharmaceuticals Funding Round
EPIRUS Biopharmaceuticals, based in Boston, secured $36 million in funding from Livzon Mabpharm, 5AM Ventures and Adage Capital Management.
Transaction Overview
Company Name
Announced On
4/17/2014
Transaction Type
Venture Equity
Amount
$36,000,000
Round
Series B
Investors
Livzon Mabpharm (Lead Investor)
5AM Ventures (Kevin Forrest)
Montreux Equity Partners (Daniel Turner)
Proceeds Purpose
Through this transaction, we gain access to additional financial resources as well as clinical trial experience in the rheumatoid arthritis space. Our combined team is committed to expanding patient access to important medications.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
699 Boylston Street 11th Floor
Boston, MA 02199
USA
Boston, MA 02199
USA
Phone
Undisclosed
Website
Email Address
Overview
The biopharmacuticals industry is approaching an unprecedented biologics patent cliff, with emerging markets forging their own regulatory landscapes. EPIRUS is seizing the opportunity with a new business model that adapts to the changing dynamics and regulations of today's market conditions.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Geoff Duyk
Chief Executive Officer
Amit Munshi
VP - Bus. Development
Gale Clark
VP - Bus. Development
Nick Plumeridge
VP - Manufacturing
Suman Patel
Browse more venture capital transactions:
Prev: 4/17/2014: SKIT venture capital transaction
Next: 4/18/2014: Profectus BioSciences venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from company press releases and news coverage. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs